Protea Inks Cancer Analysis Alliance with MSKCC, Dana-Farber | GenomeWeb

NEW YORK (GenomeWeb) – Protea Biosciences Group said today that it has undertaken a collaborative research effort with Memorial Sloan Kettering Cancer Center and the Dana-Farber Cancer Institute with an initial focus on lung cancer.

The partners will use Protea's next generation LAESI (Laser Ablation Electrospray Ionization) direct molecular imaging technology to analyze cancer cells. Protea said they will "generate molecular data profiles of cancer cells in tissue and biofluids to improve the understanding of a cancer's origin."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.